Tokyo (JST)801020Oct. 29 Friday

Oct. 30 Saturday

Epidemiology Around the World

Acute Phase and New Therapy

Chair1 Yoshikazu Nakamura

Chair 1 Hiroyuki Suzuki

Chair 1 Yukako Yoshikane

Chair2 Ermias Belay

Chair 2 Jane Newburger

Chair 2 Chisato Shimizu

Discussants： Fu ChunMin

Discussants 1 Tohru Kobayashi

30405090Discussants 2 Kevin Friedman
1. van Stijn - Bringas Dimitriades, Diana: 13-

1. Masaru Miura : Japanese new guidelines foryears of experience on Kawasaki disease in a single

treatment of Acute pohase

centre in the Netherlands

2. Koichi Miyata: Prospective Observational

2. Brian W. McCrindle: Update on theStudy on Efficacy of Acute Phase CST in aEpidemiology of Kawasaki Disease in Canada

multicenter cohort of KD PEACOCK

3.Andre Rudolph: Increase in Kawasaki disease

3. MingTai Lin: : Evaluating the Efficacy of IVIg

incidence observed in 30-year in Scandinavia+Steroid for Prevention of CAA in Taiwanese with

4. Ae Ryusuke: Epidemiology of Kawasaki disease

Refractory KD (RAST Study): a Trialin Japan, 2019–2020: the 26th nationwide survey

4. Sagiv Eyal : Etanercept with IVIg for Acute KD:

5.ChunMIn Fu: Epidemiology of Kawasaki Disease

A Long Term Follow Up on the EATAK Trialin Taiwan

5. Adri. Tremoulet Anakinra treatment in

6.Rajni Kumrah : Kawasaki disease incidence atacuteKD patients with CAA: A Phase I/IIa trial

Chandigarh, North India: 2015-2019

6. Mitsuru Seki: Prediction of response to

7. Ryan Lucas: Active Surveillance of Kawasaki

continuous cyclosporine A infusion in patients

Disease Diagnosis, Treatment, and Short-Termwith intravenous immunoglobulin-resistantOutcomes in Australia (8minutes)

Kawasaki disease
7. Grainne M Murray: Are high-risk scoring

10systems for Kawasaki disease applicable toOct. 31 Sunday
Parents Meeting：Tribute to Mr. Mitsuru Asai / Our
Hopeful Future1) Keiko Ogasawara: Tribute to Mr. Mitsuru Asai: fromJapanese Association of the Children and Parents withKawasaki Disease／The Movie Memories of Mr. M.Asai
2) Akihiko Iwakiri(Japan): The way to be with Kawasaki
Dsisease
3) Vanessa Gutierrez (USA) : A brief introduction4) Matt Nelson/Ellen Xu (USA): Update on KDF, andrecognize Greg Chin's work over the past 20 years /TheKDF youth group
5) Australia: Rebecca Wilby and Nidal Raslan : (Nidal
will only be doing the last little bit of the PowerPoint):▪KD Foundation Australia – our mission– our committee▪Our KD community▪Highlights and achievements
since the 12th IKDS▪Future plans▪KD Hero story6) Canada: Elizabeth Heald (Board Chair, Kawasaki
Disease Canada):
Free discussion

patients in the UK?
20”Tribute Session to Professor Tomisaku
30

Kawasaki”(supported by Japan HeartYuki Lynn Takahashi Memorial Lecture

Richard Rowe Memorial Session

Chair Masaru Miura

Chair Anne RowleyFoundation)
4050
10

Chair1 Yoshio Imada
Chair2 Masato Takahashi

Speaker Anne Rowley "Cloning the Plasmablast

No DiscussantResponse to Identify the Cause of Kawasaki Disease".

010VIDEO
1. Tsubura Kawasaki

20

2. J. Newburger
3. Hiroshi Yanagawa
4. Atsuko Suzuki

30

5. Marian Melish
7. J Burns

MIS-C and KD: Clinical Achievements(All speakers are designated)

Chair 1 Shuichi Ito / Chair 2 J.C. Burns
Discussant 1 Jackie Szmuszkovicz

Chair 1 Kei Takahashi

Discussant 2 Yumi Mizuno

Chair 2 Michael Portman

1. Kaneta Kelli: Distinguishing Features Between KD andDiscussant 1 Kenji Furuno

Angeles, Los Angeles

Discussant 2 Kenichiro Yamamura

2. Jerin Jose: COVID-19 Positive versus Negative Complete
Kawasaki Disease

8. Surjit Singh40

Late Breaking Session

SARS-CoV-2-Associated MIS-C 4.67 Children's Hospital Los

6. HungChi Lue and MeiHwan Wu

9. Taco Kuijpers
10. Eeva Salo50
11Speaker Kei Takahashi

３ speakers (20 minuutes for each)

3. Cedric Menlhoit :Phenotypic topology and classification of(1) J. C Burns : KIDCARE trial

pediatric patients investigated for KD and SARS-CoV-2 related(2) Moshe Arditi: Progress and Update inillnesses during the COVID-19 pandemic

Kawasaki disease pathophysiology and insights

4. Kyla Marie Cordrey: The changing profile and managementof patients diagnosed with KD before and during the SARS-CoV-20

The 1st Tomisaku Kawasaki Memorial Lecturefrom mouse models

10Chair: Mamoru Ayusawa(3) Toshiro Hara: Kawasaki Disease: its
pathogenesis and pathophysiology revisited

20pandemic

5. Daisuke Matsubara: Longitudinal Assessment of Cardiac

Speaker: Hirohisa Kato "“Insight intoOutcomes of Multisystem Inflammatory Syndrome in Children

cardiovascular issues of Kawasaki disease: My

Associated with COVID-19 Infections

6. Adriana Trmoulet: The progress of the treatment of MIS-C

milestones for 50 years” "304050

Legend Lecture (Supported by AHA)(All speakers are designated)

KD and MIS-C: Worldwide Epidemiology

KD; New Approaches in Etiology

Chair 1 Hiroyuki Yamagishi

Chair 1 Hiroyuki Matsuura

Chair 2 Min-Seob Song

Chair 2 Hiromichi Hamada

Chair 1 Anitha John: Medical Director, Washington

Discussant 1 Eisuke Suganuma

Adult Congenital Heart Program. Children's National Hospital,Discussant 2 Nagib Dahdah

George Washington University

12010

Chair 2 Adriana Tremoulet: UCSD

30

6 speakers

evolution of the International KD Registry

1. Mofors Joanna: Infections predisposing Kawasaki(1) Stanford Shulman: The history of Kawasaki

2. : Roland Ulloa-Gutierrez: Epidemiology of MIS-C in

DiseaseLaten American Children and Adolescents (MIS-C)

disease – a population-based study using the Swedish healthcare registers(2) Jane Newburger: "Treatment of Kawasaki

3. Adrian Mendez-Aguilar: MIS-C associated with SARS-

2. Menikou Stephanie: Seeking microbial origins of KD

disease: IVIG and beyond”

CoV-2 and its relation to the severe forms of KD. Study

through metagenomics of the oropharynx

from a single pediatric 3rd level facility from Mexico City

3. Rocio Gutierrez Rojas:Incidence of ethnic origins in

4. Takuya Hara: The impact of the COVID-19 State ofprovince of Quebec and related risk of developing Kawasaki

Emergency on the incidence of Kawasaki disease orDisease(3) Brian McCrindle: Evidence Gaps inGuidelines

infectious disease in Japan
5. Xie Liping: KD is not Linked to COVID-19 in Chinese
Pediatric Population

40
LunchTime
50

Discussant 2 TBA

1. Brian McCrindle: KD in the time of COVID-19 – Theassociated with COVID-19

20

Discussant１ Kazuyuki Ikeda

4. Handoko Ryan: Modulation of the severity of KD throughconcomitant environmental exposures

6. Elisa Fernández-Cooke: Prevalence and clinical

5. Wei-Ting Wang: Inflammasome Activation in KD andcharacteristics of SARS-COV-2 confirmed and negative KDMIS-C

patients during the pandemic in Spain

6. Yoshiro Nagao: Geographical Distribution of Force ofInfection were similar between KD and paediatric viral
infectious diseases in Japan

130

Sponsored Seminar 1 (Mitsubishi Tanabe
Pharma Corporation)

10

Chair: Shuji Takei

20

Speaker: Masaaki Mori

30

Sponsored Seminar 3 (NIHON

Sponsored Seminar 4 (Japan Blood Products

acute phase of Kawasaki disease

PHARMACEUTICAL CO.LTD)

Organization)

Chair: Tomoyo Matsubara

Chair: Tohru Kobayashi

Speaker: Akihiko Saitoh Infections andSpeaker 1: Shigeto Fuse Glycerin enema as a pre-Kawasaki Disease: Related or Unrelated?

treatment in the patient with Kawasaki disease.

Special Lecture
Chair: Yoshikazu Nakamura

140Lunch Time

Positioning and usefulness of infliximab at the40
50

Lunch Time

Speaker 2: Kenji Furuno Treatment of Kawasaki

Speaker: Yoshihhide Shibata: Application of datadisease in the COVID-19 epidemic. - Do we need to beanalysis and numerical modeling technics inaware of the difference between 5% and 10% solutions?

engineering to the medical data analysis
1020
Diagnosis / Clinical Examinations

JSKD-APSC joint session ' Prospect of Asian
Guidelines for CV complications of Kawasaki

30

Cardiovascular Complications

Disease'40

Chair 1 Tohru Kobayashi

Chair 1 Yoshihide Mitani

Chair 1 Kenji Suda

Chair 2 MingTai Lin

Chair 2 MeiHwan-Wu

Chair 2 John Gordon

Discussants 1 Yuichi Nomura

Discussants 1 Hiroyoshi Yokoi

Discussant 1 Kentaro Aso

Discussants 2 TBA

Department of Health Science, International University

Discussant 2 Fujito Numanoof Health and Welfare, Fukuoka

50

Discussants 2 Lucy Youngmin Eun
Division of Pediatric Cardiology, Department ofPediatrics, Yonsei University College of Medicine,1506 speakers

5 speakers:(All speakers are designated)

1.Etsuko Tsuda : Characteristics of coronary flow velocity

1 （designated）Ayusawa Mamoru

1 Ryuji Fukazawa (15min)reserve on transthoracic Doppler echocardiography in patients with

he 6th Revision of Japanese Diagnostic Criteria

Department of Pediatrics, Nippon Medical School,a history of KD

2 (designated) Ming Tai LinTokyo, Japan

2. Jennifer JI Lee The Hospital for Sick Children: The Long-Techniques and Pitfalls in Coronary Echo-

2 Ming-Tai LIN （15min）term Cardiac and Non-Cardiac Prognosis of KD - A Systematic

cardiography in KD patient
103 Yukako Yoshikane
Biomarkers of Tenascin C and Pentraxin 3 Predict

2030

University Hospital and Medical College,
National Taiwan University, Taipei, Taiwan.
3 Yoshihide Mitani (15min)

Review

3. Taichi Kato Nagoya University Graduate School of Medicine:
Analysis of the long-term clinical course and the factors asspciatedwith coronary arterial aneurysm regression in Kawasaki disease
patients

the Treatment-Registant Kawasaki Disease

Department of Pediatrics, Mie University

4 Micheal Portman

Graduate School of Medicine, Tsu, Mie, Japan

Artifical Interlligence Derived Proteoomic Panel to4 Sidney Lo （15min）

Diagnose Kawasaki Disease

Department of Cardiology, Liverpool Hospital andComparison of Coronary Artery Dimensions on CT Coronary

5. Nicholas Dreger Impact of Coronary Artery Z-South Western Sydney Clinical School,Angiography with 2D Echocardiography in Children with Kawasaki

score Models on the Classification of Coronary

The University of New South Wales, Sydney,

Disease: A Study from Chandigarh, North India

Involvement and Management of<br/>Kawasaki

NSW, Australia

6. Hiroyuki Ohashi : Potential Substrates for Acute Coronary

5 Dr Khung Keong (KK) Yeo （15min）Syndrome in Adults Long after Kawasaki Disease with Severe

Disease6 Larios Guillermo

Coronary arteries Z-Scores inKawasaki disease. Are the different nomograms
40

Department of Pediatrics, National Taiwan

Department of Cardiology, National Heart Center

4. Jane C. Burns University of California San Diego
Coronary artery remodeling after Kawasaki disease

5. Manphool Singhal

Coronary Artery Involvement: In Vivo Unprecedented Optical
Coherence Tomography Based Phenotyping of Coronary Sequelae

Singapore, Singapore

comparable?

50
16010Pathogenesis and Gentics

Animal model / immunology/Novel experiment(Basic research)

Long term management and Transition
Chair 1 Etsuko Tsuda
Chair 2 Ryuji Fukazawa

Chair 1 Yoshihiro Onouchi

Chair 1 Roland Cimaz

Discussant 1 Masahiro Kamada

Chair 2 Surjit Singh

Chair 2 Masaaki Mori

Discussant 2 Motofumi Iemura
1. Tsuchihashi Tomoya : Intimal thickening and20DiscussantJun Abe : Natioal Center of Child Healthand Development

Discussant 1 Toshiaki Oharaseki

disruption of the media occur in the arterial walls of CADiscussant 2 Masaki Shimizu

not associated with CAL in patients with KD
2. Krsten Dummer: The Use of Direct Oral

304050170

1. Keynote: Yoshihiro Onouchi; Newer

7 speakers

development of genetic study of KD

1. Teramoto Yoshiki: Gut microbiota as a

2. Xue Fansusceptibility factor for Kawasaki disease

Expression profile analysis of Differentially Expressed

2. Marek Iannucci Stefanie : Autophagy-

Genes in Human Coronary Artery Endothelial Cells

mitophagy induction attenuates cardiovascular

Induced by Serum from KD: A preliminary study

inflammation in a murine model of KD vasculitis by

3. Heather Jackson

modulating the NLRP3 inflammasome.

KD Patient Stratification and Pathway Analysis Based

3. Ben Croker : Intravenous immunoglobulin ison Host Transcriptomic and Proteomic Profiles

associated with the elimination of IL-1β expressing

Kawasaki patients

4. Sadeep Shrestha

neutrophils in patients with KD and MIS-C (change ?)5. Kato Masataka: 'Clinical Significance of Perivascular

Whole-Genome Sequencing Analysis of IVIG response

4. Chisato Shimizu: Endotherial cell response toAdipose Tissue Heterogeneity in KD with CAL

among KD patients

atrovaatatin

6. Kanae Tsuno : Evaluation of the coronary circulation

5. Ryusuke Ae

5. Rebecca Poritt: Single-cell and spatialby 13N-ammonia PET in the coronary artery lesion afterKD and pediatric infectious diseases during thetranscriptomics reveal NLRP3 inflammasome-mediatedKDcoronavirus disease 2019 pandemic

6. Vishnuvardhan Reddy Konda
10Nail-fold capillaroscopy changes in a single center
cohort of patients with KD from North-West India

20

immune-stromal interactions during vasculitis andcardiovascular inflammation

6. Akio Matsuda: Screening for novel drug candidates
for treatment of IVIG-resistant Kawasaki disease

Anticoagulants in Patients with Giant Coronary Atery
Aneurysms related to KD
3. Eisuke Suganuma: The effect of ARB/ACEi forregression of coronary aneurysm in KD patients: asubgroup analysis of the KIDCAR study (EARNEST)4. Kathrine Hansen: Physicians’ self-reported exercise
testing and physical activity recommendations in30

Sponsored Seminar 2 (Teijin Pharma Limited)

Chair: Mamoru Ayusawa
40

Speaker: Hiromichi Hamada
Cooperation of Kawasaki disease medical care inAsia and its future perspective

50

18010

Moderated Poster (1)Moderated Poster (2)Chair 1 : Masahiro Ishii

Chair 1 : Tomoyo Matsubara

Chair 2 : Taco Kuijpers

Chair 2 : Bregel Lyudmila

1) Nita Chahal: The psychosocial reality for1)Jong-Woon Choi: Epidemiology and Clinical Outcomesadolescents and parents living with KDof Refractory Kawasaki Disease in Korea

complicated by coronary artery aneurysms

2) Toshimasa Nakada: Acute Phase Treatment and2)Marianna Fabi: Gut microbiota dysbiosis in KD

Medium-Term Outcomes in Kawasaki Diseasea perspective<br>comparative study3) Chen Chu: The safety of statin in early and middle3)John Kanegaye: Dipstick and automatedstage after medication in children with Kawasaki disease

microscopic urinalysis (UA) to differentiate KD

complicated with coronary aneurysms

from UTI, the MIS-C, and other causes of fever

4) Himanshi Chaudhary: Pan Coronary Artery

4) KUO HO-CHANG: Intravenous Immunoglobulin

Involvement’ in Kawasaki Disease: a unique and hitherto

Treatment in KD Decreases the Incidence ofunreported finding on Computed Tomography CoronaryMyopia

Angiography5) Bregel Lyudmila: Macrophage activation

5) Michael Fridman: The Utility of Cardiac Biomarkers

syndrome in Kawasaki Disease <br/>and MIS-C

in the Differentiation and Prognostication of KDversus

with COVID-19

MIS-C Associated with COVID-196) Cole Lyndsey: Fulfillment of KD criteria and6) Paul Tsoukas: Proton pump inhibitors suppress IL-1

associated outcomes in MIS-C

mediated carditis in a murine model of KD